Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM

    Nephrology Dialysis Transplantation Date published:

  • FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER

    Nephrology Dialysis Transplantation Date published:

  • FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER

    Nephrology Dialysis Transplantation Date published:

  • Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

    Circulation Date published:

  • Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Kidney International Date published:

  • Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC)

    BMJ Open Date published:

  • Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    The Lancet Date published:

  • Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

    Nephrology Date published:

  • Effect of extended hours dialysis on sleep quality in a randomized trial

    Nephrology Date published:

  • Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

    Diabetologia Date published:

  • Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study

    PLOS ONE Date published:

  • Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial

    Canadian Medical Association Journal Date published:

  • EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM

    Journal of the American College of Cardiology Date published:

  • Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study

    BMJ Open Date published:

  • Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

    The Lancet Diabetes & Endocrinology Date published: